Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Game-changing offering leverages the power of machine learning to fill critical information gaps in the early-stage pharmaceutical pipeline.
Evaluate Ltd., a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, today announces that it has secured additional…
“Pharma, Biotech and Medtech Half-Year Review 2020” analyses the market performance and deal landscape for the first half of 2020, focusing on the impact of COVID-19
The impact of COVID-19 has so far wiped $7.85bn off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss, according to the…
COVID-19 Virtual Partnering is a unique and free-to-attend virtual event taking place on 20 April – 06 May. The initiative is backed by a consortium of biotech clusters…
Evaluate Ltd., the leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, is delighted to announce today that it has…
Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of…